Compounding Diabetes Documentation 
STAT
OCTOBER 22, 2024
Novo Nordisk has asked the Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make. The FDA still has to make a decision on whether to officially place semaglutide on the lists.
STAT
DECEMBER 4, 2024
It mirrors results seen in the companies’ diabetes drugs, which use the same active ingredients. But documenting the differences between Zepbound and Wegovy in a rigorous way might allow Lilly to make marketing claims about Zepbound’s superior efficacy. That, in turn, could help the company gain market share against Novo.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
STAT
OCTOBER 23, 2024
Food and Drug Administration to bar compounding pharmacies from making copies of its blockbuster weight loss drug semaglutide, arguing that the medication is too complex for the pharmacies to safely make , STAT reports. Novo has repeatedly argued that compounded products are risky, stressing that they are not approved by the FDA.
STAT
NOVEMBER 18, 2022
The document says that public funding for the development of vaccines and treatments should be more transparent, and include provisions to ensure that any resulting products are distributed evenly around the world. The first therapy that delays the onset of type 1 diabetes received approval from the U.S. As of 2019, about 1.9
pharmaphorum
JULY 28, 2022
Supply chain challenges are compounded by the broader global picture, such as the war in Ukraine, the great resignation, and natural disasters. Many of the medicines most badly affected by these shortages are generic drugs to treat common conditions such as diabetes and heart disease.
Pharmaceutical Technology
SEPTEMBER 7, 2022
The rising incidence of long-standing diseases such as hypertension, diabetes, cardiovascular diseases, and cancer requires prolonged medication and, thus, drives the growth and need for retail pharmacies in the market. Compounding services. Speciality care. Pharmacogenetics testing. Filling services. Prescription collection lockers.
European Pharmaceutical Review
JUNE 27, 2022
The €156 million initiative identifies effective actions and the available legal and financial supporting tools across five main areas: cardiovascular diseases, diabetes, chronic respiratory diseases, mental health and neurological disorders, as well as their main contributing factors.
Expert insights. Personalized for you.
362 
Let's personalize your content